Reaction
Follicular Lymphoma Refractory reporting signals
As of the last recalculation, Follicular Lymphoma Refractory appears in 59 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is OBINUTUZUMAB (PRR 996.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Obinutuzumab | 26 | 996.1 | 997.6 |
| Bendamustine Hcl | 22 | 797.5 | 798.6 |
| Bendamustine Hydrochloride | 7 | 233.8 | 234.0 |